ResMed upgraded at RBC Capital Markets on Q4 positives
RBC Capital Markets on Tuesday upgraded ResMed NYSE:RMD to Outperform from Sector Perform and raised its price target to $262 from $244, citing positives in the respiratory device maker’s Q4 results for fiscal 2026.Shares of ResMed NYSE:RMD fell in early August as investors reacted to its Q4 FY26 r…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.